No Antiplatelet Strategy Post-TAVR Showed Similar NACE, Lower Bleeding Rates vs. SAPT or DAPT: OCEAN-TAVI Registry

Need an Account?

Content is available to registered users only. Registration is free.

Register now, or if you’ve already registered, log in.
News

No Antiplatelet Strategy Post-TAVR Showed Similar NACE, Lower Bleeding Rates vs. SAPT or DAPT: OCEAN-TAVI Registry

Posted: 01/09/2023
Author:
Sukhdeep Bhogal, CRTonline.org
Thrombosis News Articles Transcatheter Aortic Valve Replacement Aortic Valve Interventions Antiplatelet Therapy 2023 Bleeding Complications Valve & Structural Cardiovascular Pharmacology

No antithrombotic therapy was associated with a comparable rate of net adverse clinical events (NACEs) to single-antiplatelet therapy (SAPT) or dual-antiplatelet therapy (DAPT), according to a new OCEAN-TAVI Registry analysis.

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Need an Account?

News

No Antiplatelet Strategy Post-TAVR Showed Similar NACE, Lower Bleeding Rates vs. SAPT or DAPT: OCEAN-TAVI Registry

Most Viewed Pages

Explore the Site

Stay Connected